All Type of News
Cashable assets owned by listed pharma are reaching for KRW 2 trillion
Cashable assets owned by listed pharmaceutical companies are reaching for KRW 2 trillion.
According to the Yakup Shinmoon’s(www.yakup.com) analysis result of 2016 3rd quarter reports turned in by KOSPI and KOSDAQ li...
MOHW, “We will actively provide supports for innovative pharmas”
The Ministry of Health and Welfare(MOHW) announced to more aggressively support innovative pharmaceutical companies.
Joo-Young Kim, Health Industry Development Division Director at the Ministry of Health and Welfare,...
Kuhnil about to acquire approval of world’s first children sleep medication
On the 23rd of November, Kuhnil Pharm(CEO Young-Joong Kim, Jae-Hee Choi) announced it was informed the Phase 3 clinical trial of Circadilly that will be introduced from Israeli Neurim was successfully completed.
Circ...
Listed pharmas increase advertising expenses by 14%
Listed pharmaceutical companies’ advertising expenses were increased by 14% over the last year. Moreover, there were 4 pharmaceutical companies which spent more than KRW 30 billion in advertisement between January and...
Effect of Kim Young-Ran Law made pharmas cut entertainment expenses
It was observed entertainment expenses for listed pharmaceutical companies were increased by 7% compared to the last year. Particularly, the rate of entertainment expenses against sales by the first half was similar w...
‘Celltrion’ becomes top in spending R&D expenses
The KOSDAQ listed pharmaceutical companies’ average R&D expense/sales rate in the 3rd quarter exceeded 10%, and the one for KOSPI listed pharmaceutical companies did not reach 10%.
According to the Yakup Shinmoon’s(w...
FTC imposes corrective measures on Boehringer to dispose its animal drugs
Boehringer Ingelheim was given corrective measures to its dispose assets related to sales of its porcine circovirus vaccine and oral nonsteroidal anti-inflammatory drug(NSAID) for use in dogs in Korea.
On the 23rd, t...
I-SENS acquires U.S. diagnostic device company ‘CoaguSense’
On the 22nd, a biosensor company, I-SENS(CEO Geun-Sig Cha), signed an agreement to acquire 62% of the share of a U.S. blood coagulation monitoring company ‘CoaguSense’ and its control for USD 10.4 million.
According ...
Fierce competition expected among hepatitis C therapies, triggered by Zepatier’s approval
Another competitor showed up in the Korean hepatitis C therapy market where Gilead and BMS are competing each other.
According to the industry concerned on the 22nd, the Korea MSD’s hepatitis C therapy ‘Zepatier(elba...
Large differences of cancer incidence in different regions
It was analyzed cancer incidence rates in different cities, districts and provinces vary from double to 15 times higher.
The Ministry of Health and Welfare(Minister Jin-Yup Jung) and Korea Central Cancer Registry(Nat...
